T Cell Cosignaling Molecules in Transplantation

Immunity

Volumn 44, Issue 5, 2016, Pages 1020-1033

  Ford, Mandy L ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BELATACEPT; CD134 ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1H; RAPAMYCIN; T CELL IMMUNOGLOBULIN MUCIN; T CELL IMMUNOGLOBULIN MUCIN 1; T CELL IMMUNOGLOBULIN MUCIN 3; T CELL IMMUNOGLOBULIN MUCIN 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; SIGNAL PEPTIDE; TIMELESS PROTEIN, HUMAN;

ALLOIMMUNITY; ANTIBODY SPECIFICITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTRACELLULAR SIGNALING; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; ALLOTRANSPLANTATION; ANIMAL; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE; TRENDS;

ANIMALS; ANTIGENS, CD28; CELL CYCLE PROTEINS; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84966747146     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.04.012     Document Type: Review

References (167)

1. Adams A.B., Williams M.A., Jones T.R., Shirasugi N., Durham M.M., Kaech S.M., Wherry E.J., Onami T., Lanier J.G., Kokko K.E., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 2003, 111:1887-1895.
2. Adams A.B., Shirasugi N., Jones T.R., Durham M.M., Strobert E.A., Cowan S., Rees P., Hendrix R., Price K., Kenyon N.S., et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 2005, 174:542-550.
3. Anderson A., Joller N., Kuchroo V. Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016, 44:989-1004. this issue.
4. Aoyagi T., Yamashita K., Suzuki T., Uno M., Goto R., Taniguchi M., Shimamura T., Takahashi N., Miura T., Okimura K., et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am. J. Transplant. 2009, 9:1732-1741.
5. Azuma M., Phillips J.H., Lanier L.L. CD28- T lymphocytes. Antigenic and functional properties. J. Immunol. 1993, 150:1147-1159.
6. Badell I.R., Russell M.C., Thompson P.W., Turner A.P., Weaver T.A., Robertson J.M., Avila J.G., Cano J.A., Johnson B.E., Song M., et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J. Clin. Invest. 2010, 120:4520-4531.
7. Badell I.R., Russell M.C., Cardona K., Shaffer V.O., Turner A.P., Avila J.G., Cano J.A., Leopardi F.V., Song M., Strobert E.A., et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am. J. Transplant. 2012, 12:1918-1923.
8. Badell I.R., Thompson P.W., Turner A.P., Russell M.C., Avila J.G., Cano J.A., Robertson J.M., Leopardi F.V., Strobert E.A., Iwakoshi N.N., et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am. J. Transplant. 2012, 12:126-135.
9. Batliwalla F., Monteiro J., Serrano D., Gregersen P.K. Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation?. Hum. Immunol. 1996, 48:68-76.
10. Bengsch B., Seigel B., Ruhl M., Timm J., Kuntz M., Blum H.E., Pircher H., Thimme R. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 2010, 6:e1000947.
11. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
12. Boenisch O., D'Addio F., Watanabe T., Elyaman W., Magee C.N., Yeung M.Y., Padera R.F., Rodig S.J., Murayama T., Tanaka K., et al. TIM-3: a novel regulatory molecule of alloimmune activation. J. Immunol. 2010, 185:5806-5819.
13. Brimhall A.K., King L.N., Licciardone J.C., Jacobe H., Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br. J. Dermatol. 2008, 159:274-285.
14. Brown D.R., Calpe S., Keszei M., Wang N., McArdel S., Terhorst C., Sharpe A.H. Cutting edge: an NK cell-independent role for Slamf4 in controlling humoral autoimmunity. J. Immunol. 2011, 187:21-25.
15. Burghuber C.K., Kwun J., Page E.J., Manook M., Gibby A.C., Leopardi F.V., Song M., Farris A.B., Hong J.J., Villinger F., et al. Antibody mediated rejection in sensitized non-human primates: modeling human biology. Am. J. Transplant. 2015, Published online December 24, 2015. 10.1111/ajt.13688.
16. Burrell B.E., Lu G., Li X.C., Bishop D.K. OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J. Immunol. 2009, 182:379-390.
17. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
18. Cai L., Zhou H., Fang Z., Yuan J., Niki T., Hirashima M., He W., Chen Z.K. Galectin-9 in combination with rapamycin induces cardiac allograft tolerance in mice. Transplantation 2013, 96:379-386.
19. Chadha R., Heidt S., Jones N.D., Wood K.J. Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance?. Transplantation 2011, 91:939-945.
20. Charbonnier L.M., Vokaer B., Lemaître P.H., Field K.A., Leo O., Le Moine A. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am. J. Transplant. 2012, 12:2313-2321.
21. Chen J., Yin H., Xu J., Wang Q., Edelblum K.L., Sciammas R., Chong A.S. Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am. J. Transplant. 2013, 13:2280-2292.
22. Daley S.R., Cobbold S.P., Waldmann H. Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. Am. J. Transplant. 2008, 8:2265-2271.
23. Degauque N., Mariat C., Kenny J., Zhang D., Gao W., Vu M.D., Alexopoulos S., Oukka M., Umetsu D.T., DeKruyff R.H., et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J. Clin. Invest. 2008, 118:735-741.
24. Ding Q., Yeung M., Camirand G., Zeng Q., Akiba H., Yagita H., Chalasani G., Sayegh M.H., Najafian N., Rothstein D.M. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 2011, 121:3645-3656.
25. Dong C., Juedes A.E., Temann U.A., Shresta S., Allison J.P., Ruddle N.H., Flavell R.A. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001, 409:97-101.
26. Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009, 229:152-172.
27. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 2001, 345:248-255. Alefacept Clinical Study Group.
28. Esensten J.H., Helou Y.A., Chopra G., Weiss A., Bluestone J.A. CD28 costimulation: from mechanism to therapy. Immunity 2016, 44:973-988. this issue.
29. Ezzelarab M.B., Ekser B., Isse K., Iwase H., Morelli A.E., Ayares D., Cooper D.K. Increased soluble CD154 (CD40 ligand) levels in xenograft recipients correlate with the development of de novo anti-pig IgG antibodies. Transplantation 2014, 97:502-508.
30. Ferrer I.R., Wagener M.E., Song M., Kirk A.D., Larsen C.P., Ford M.L. Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade. Proc. Natl. Acad. Sci. USA 2011, 108:20701-20706.
31. Ferrer I.R., Liu D., Pinelli D.F., Koehn B.H., Stempora L.L., Ford M.L. CD40/CD154 blockade inhibits dendritic cell expression of inflammatory cytokines but not costimulatory molecules. J. Immunol. 2012, 189:4387-4395.
32. Ferrer I.R., Wagener M.E., Song M., Ford M.L. CD154 blockade alters innate immune cell recruitment and programs alloreactive CD8+ T cells into KLRG-1(high) short-lived effector T cells. PLoS ONE 2012, 7:e40559.
33. Flies D.B., Wang S., Xu H., Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 2011, 187:1537-1541.
34. + T cell-mediated immunity. J. Clin. Invest. 2014, 124:1966-1975.
35. Flies D.B., Higuchi T., Chen L. Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens. J. Immunol. 2015, 194:5294-5304.
36. Ford M.L., Larsen C.P. Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations. Curr. Opin. Organ Transplant. 2010, 15:405-410.
37. Ford M.L., Koehn B.H., Wagener M.E., Jiang W., Gangappa S., Pearson T.C., Larsen C.P. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J. Exp. Med. 2007, 204:299-309.
38. Gilson C.R., Milas Z., Gangappa S., Hollenbaugh D., Pearson T.C., Ford M.L., Larsen C.P. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J. Immunol. 2009, 183:1625-1635.
39. Gorbacheva V., Fan R., Wang X., Baldwin W.M., Fairchild R.L., Valujskikh A. IFN-γ production by memory helper T cells is required for CD40-independent alloantibody responses. J. Immunol. 2015, 194:1347-1356.
40. Gupta S., Thornley T.B., Gao W., Larocca R., Turka L.A., Kuchroo V.K., Strom T.B. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J. Clin. Invest. 2012, 122:2395-2404.
41. Haanstra K.G., Ringers J., Sick E.A., Ramdien-Murli S., Kuhn E.M., Boon L., Jonker M. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003, 75:637-643.
42. He W., Fang Z., Wang F., Wu K., Xu Y., Zhou H., Du D., Gao Y., Zhang W.N., Niki T., et al. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation 2009, 88:782-790.
43. Higginbotham L., Mathews D., Breeden C.A., Song M., Farris A.B., Larsen C.P., Ford M.L., Lutz A.J., Tector M., Newell K.A., et al. Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model. Xenotransplantation 2015, 22:221-230.
44. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., Kroczek R.A. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
45. Imai A., Suzuki T., Sugitani A., Itoh T., Ueki S., Aoyagi T., Yamashita K., Taniguchi M., Takahashi N., Miura T., et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007, 84:1020-1028.
46. Ito T., Ueno T., Clarkson M.R., Yuan X., Jurewicz M.M., Yagita H., Azuma M., Sharpe A.H., Auchincloss H., Sayegh M.H., Najafian N. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 2005, 174:6648-6656.
47. Johnson S., Zhan Y., Sutherland R.M., Mount A.M., Bedoui S., Brady J.L., Carrington E.M., Brown L.E., Belz G.T., Heath W.R., Lew A.M. Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 2009, 30:218-227.
48. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 2000, 6:114.
49. Kim J.R., Mathew S.O., Patel R.K., Pertusi R.M., Mathew P.A. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010, 160:348-358.
50. Kim E.J., Kwun J., Gibby A.C., Hong J.J., Farris A.B., Iwakoshi N.N., Villinger F., Kirk A.D., Knechtle S.J. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am. J. Transplant. 2014, 14:59-69.
51. Kinnear G., Wood K.J., Marshall D., Jones N.D. Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection. Transplantation 2010, 90:1265-1271.
52. Kinnear G., Wood K.J., Fallah-Arani F., Jones N.D. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen. J. Immunol. 2013, 191:1465-1475.
53. Kirk A.D., Tadaki D.K., Celniker A., Batty D.S., Berning J.D., Colonna J.O., Cruzata F., Elster E.A., Gray G.S., Kampen R.L., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001, 72:377-384.
54. Kitchens W.H., Haridas D., Wagener M.E., Song M., Kirk A.D., Larsen C.P., Ford M.L. Integrin Antagonists Prevent Costimulatory Blockade-Resistant Transplant Rejection by CD8(+) Memory T Cells. Am. J. Transplant. 2012.
55. Koehn B.H., Ford M.L., Ferrer I.R., Borom K., Gangappa S., Kirk A.D., Larsen C.P. PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. J. Immunol. 2008, 181:5313-5322.
56. Krummey S.M., Ford M.L. Heterogeneity within T Cell Memory: Implications for Transplant Tolerance. Front. Immunol. 2012, 3:36.
57. Krummey S.M., Cheeseman J., Conger J.A., Jang P.S., Mehta A.K., Kirk A.D., Larsen C.P., Ford M.L. High CTLA-4 Expression on Th17 Cells Results in Increased Sensitivity to CTLA-4 Coinhibition and Resistance to Belatacept. Am. J. Transplant 2013, 14:607-614.
58. Lácha J., Bushell A., Smetana K., Rossmann P., Pribylová P., Wood K., Malý P. Intercellular cell adhesion molecule-1 and selectin ligands in acute cardiac allograft rejection: a study on gene-deficient mouse models. J. Leukoc. Biol. 2002, 71:311-318.
59. Laouar A., Manocha M., Wan M., Yagita H., van Lier R.A., Manjunath N. Cutting Edge: Distinct NK receptor profiles are imprinted on CD8 T cells in the mucosa and periphery during the same antigen challenge: role of tissue-specific factors. J. Immunol. 2007, 178:652-656.
60. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., Cho H.R., Aruffo A., Hollenbaugh D., Linsley P.S., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
61. Larsen C.P., Pearson T.C., Adams A.B., Tso P., Shirasugi N., Strobert E., Anderson D., Cowan S., Price K., Naemura J., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 2005, 5:443-453.
62. Lee K.M., McNerney M.E., Stepp S.E., Mathew P.A., Schatzle J.D., Bennett M., Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J. Exp. Med. 2004, 199:1245-1254.
63. Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., Linsley P.S., Bluestone J.A. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992, 257:789-792.
64. Lenschow D.J., Zeng Y., Hathcock K.S., Zuckerman L.A., Freeman G., Thistlethwaite J.R., Gray G.S., Hodes R.J., Bluestone J.A. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 1995, 60:1171-1178.
65. Li W., Zheng X.X., Kuhr C.S., Perkins J.D. CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance. Am. J. Transplant. 2005, 5:978-986.
66. Lin H., Bolling S.F., Linsley P.S., Wei R.Q., Gordon D., Thompson C.B., Turka L.A. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 1993, 178:1801-1806.
67. Linsley P.S., Nadler S.G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev. 2009, 229:307-321.
68. Liu D., Ferrer I.R., Konomos M., Ford M.L. Inhibition of CD8+ T cell-derived CD40 signals is necessary but not sufficient for Foxp3+ induced regulatory T cell generation in vivo. J. Immunol. 2013, 191:1957-1964.
69. Liu D., Krummey S.M., Badell I.R., Wagener M., Schneeweis L.A., Stetsko D.K., Suchard S.J., Nadler S.G., Ford M.L. 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. J. Exp. Med. 2014, 211:297-311.
70. Liu D., Suchard S.J., Nadler S.G., Ford M.L. Inhibition of Donor-Reactive CD8+ T Cell Responses by Selective CD28 Blockade Is Independent of Reduced ICOS Expression. PLoS ONE 2015, 10:e0130490.
71. Liu Y., Ji H., Zhang Y., Shen X., Gao F., He X., Li G.A., Busuttil R.W., Kuchroo V.K., Kupiec-Weglinski J.W. Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury. J. Hepatol. 2015, 62:563-572.
72. Liu Y., Ji H., Zhang Y., Shen X.D., Gao F., Nguyen T.T., Shang X., Lee N., Busuttil R.W., Kupiec-Weglinski J.W. Negative CD4c+cTIM-3 signaling confers resistance against cold preservation damage in mouse liver transplantation. Am. J. Transplant. 2015, 15:954-964.
73. Lo D.J., Weaver T.A., Stempora L., Mehta A.K., Ford M.L., Larsen C.P., Kirk A.D. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am. J. Transplant. 2011, 11:22-33.
74. Lo D.J., Anderson D.J., Weaver T.A., Leopardi F., Song M., Farris A.B., Strobert E.A., Jenkins J., Turgeon N.A., Mehta A.K., et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am. J. Transplant. 2013, 13:320-328.
75. Lo D.J., Anderson D.J., Song M., Leopardi F., Farris A.B., Strobert E., Chapin S., Devens B., Karrer E., Kirk A.D. A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation. Am. J. Transplant. 2015, 15:984-992.
76. Lowe M., Badell I.R., Thompson P., Martin B., Leopardi F., Strobert E., Price A.A., Abdulkerim H.S., Wang R., Iwakoshi N.N., et al. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am. J. Transplant. 2012, 12:2079-2087.
77. Lowe M.C., Badell I.R., Turner A.P., Thompson P.W., Leopardi F.V., Strobert E.A., Larsen C.P., Kirk A.D. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am. J. Transplant. 2013, 13:312-319.
78. Merrill J.T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D.J., Bae S.C., Sigal L., Becker J.C., Kelly S., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62:3077-3087.
79. Moingeon P., Chang H.C., Wallner B.P., Stebbins C., Frey A.Z., Reinherz E.L. CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature 1989, 339:312-314.
80. Monk N.J., Hargreaves R.E., Marsh J.E., Farrar C.A., Sacks S.H., Millrain M., Simpson E., Dyson J., Jurcevic S. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat. Med. 2003, 9:1275-1280.
81. Nanji S.A., Hancock W.W., Luo B., Schur C.D., Pawlick R.L., Zhu L.F., Anderson C.C., Shapiro A.M. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes 2006, 55:27-33.
82. Nicolls M.R., Gill R.G. LFA-1 (CD11a) as a therapeutic target. Am. J. Transplant. 2006, 6:27-36.
83. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., Angeli V., Li Y., Boros P., Ding Y., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 2006, 7:652-662.
84. Okwor I., Jia P., Uzonna J.E. Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major. J. Immunol. 2015, 195:3218-3226.
85. Oura T., Yamashita K., Suzuki T., Fukumori D., Watanabe M., Hirokata G., Wakayama K., Taniguchi M., Shimamura T., Miura T., et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am. J. Transplant. 2012, 12:1740-1754.
86. Ozkaynak E., Gao W., Shemmeri N., Wang C., Gutierrez-Ramos J.C., Amaral J., Qin S., Rottman J.B., Coyle A.J., Hancock W.W. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2001, 2:591-596.
87. Ozkaynak E., Wang L., Goodearl A., McDonald K., Qin S., O'Keefe T., Duong T., Smith T., Gutierrez-Ramos J.C., Rottman J.B., et al. Programmed death-1 targeting can promote allograft survival. J. Immunol. 2002, 169:6546-6553.
88. Page A., Srinivasan S., Singh K., Russell M., Hamby K., Deane T., Sen S., Stempora L., Leopardi F., Price A.A., et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am. J. Transplant. 2012, 12:115-125.
89. Pearson T.C., Alexander D.Z., Winn K.J., Linsley P.S., Lowry R.P., Larsen C.P. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994, 57:1701-1706.
90. Pearson T.C., Alexander D.Z., Corbascio M., Hendrix R., Ritchie S.C., Linsley P.S., Faherty D., Larsen C.P. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997, 63:1463-1469.
91. Pearson T.C., Trambley J., Odom K., Anderson D.C., Cowan S., Bray R., Lin A., Hollenbaugh D., Aruffo A., Siadak A.W., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002, 74:933-940.
92. Pinelli D.F., Ford M.L. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy 2015, 7:399-410.
93. Pinelli D.F., Wagener M.E., Liu D., Yamniuk A., Tamura J., Grant S., Larsen C.P., Suri A., Nadler S.G., Ford M.L. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. Am. J. Transplant. 2013, 13:3021-3030.
94. Poirier N., Azimzadeh A.M., Zhang T., Dilek N., Mary C., Nguyen B., Tillou X., Wu G., Reneaudin K., Hervouet J., et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2010, 2:17ra10.
95. Ponciano V.C., Renesto P.G., Nogueira E., Rangel E.B., Cenedeze M.A., Franco M.F., Câmara N.O., Pacheco-Silva A. Tim-3 expression in human kidney allografts. Transpl. Immunol. 2007, 17:215-222.
96. Posselt A.M., Bellin M.D., Tavakol M., Szot G.L., Frassetto L.A., Masharani U., Kerlan R.K., Fong L., Vincenti F.G., Hering B.J., et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am. J. Transplant. 2010, 10:1870-1880.
97. Poston R.S., Robbins R.C., Chan B., Simms P., Presta L., Jardieu P., Morris R.E. Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation 2000, 69:2005-2013.
98. Quezada S.A., Jarvinen L.Z., Lind E.F., Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 2004, 22:307-328.
99. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., Baker J., Jeffery L.E., Kaur S., Briggs Z., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
100. Rabant M., Gorbacheva V., Fan R., Yu H., Valujskikh A. CD40-independent help by memory CD4 T cells induces pathogenic alloantibody but does not lead to long-lasting humoral immunity. Am. J. Transplant. 2013, 13:2831-2841.
101. Rahman A.H., Cui W., Larosa D.F., Taylor D.K., Zhang J., Goldstein D.R., Wherry E.J., Kaech S.M., Turka L.A. MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J. Immunol. 2008, 181:3804-3810.
102. Rayat G.R., Gill R.G. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes 2005, 54:443-451.
103. Raziorrouh B., Schraut W., Gerlach T., Nowack D., Gruner N.H., Ulsenheimer A., Zachoval R., Wachtler M., Spannagl M., Haas J., et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010, 52:1934-1947.
104. Reisman N.M., Floyd T.L., Wagener M.E., Kirk A.D., Larsen C.P., Ford M.L. LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. Blood 2011, 118:5851-5861.
105. Renesto P.G., Ponciano V.C., Cenedeze M.A., Saraiva Câmara N.O., Pacheco-Silva A. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am. J. Transplant. 2007, 7:1661-1665.
106. Rey J., Giustiniani J., Mallet F., Schiavon V., Boumsell L., Bensussan A., Olive D., Costello R.T. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. Eur. J. Immunol. 2006, 36:2359-2366.
107. Riella L.V., Liu T., Yang J., Chock S., Shimizu T., Mfarrej B., Batal I., Xiao X., Sayegh M.H., Chandraker A. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am. J. Transplant. 2012, 12:846-855.
108. Rozanski C.H., Arens R., Carlson L.M., Nair J., Boise L.H., Chanan-Khan A.A., Schoenberger S.P., Lee K.P. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J. Exp. Med. 2011, 208:1435-1446.
109. Sabatos C.A., Chakravarti S., Cha E., Schubart A., Sánchez-Fueyo A., Zheng X.X., Coyle A.J., Strom T.B., Freeman G.J., Kuchroo V.K. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 2003, 4:1102-1110.
110. Sage P.T., Paterson A.M., Lovitch S.B., Sharpe A.H. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014, 41:1026-1039.
111. Sánchez-Fueyo A., Tian J., Picarella D., Domenig C., Zheng X.X., Sabatos C.A., Manlongat N., Bender O., Kamradt T., Kuchroo V.K., et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 2003, 4:1093-1101.
112. Sandborn W.J., Colombel J.F., Sands B.E., Rutgeerts P., Targan S.R., Panaccione R., Bressler B., Geboes K., Schreiber S., Aranda R., et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012, 143:62-69 e64.
113. Sanders M.E., Makgoba M.W., Sharrow S.O., Stephany D., Springer T.A., Young H.A., Shaw S. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J. Immunol. 1988, 140:1401-1407.
114. Sandner S.E., Clarkson M.R., Salama A.D., Sanchez-Fueyo A., Domenig C., Habicht A., Najafian N., Yagita H., Azuma M., Turka L.A., Sayegh M.H. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 2005, 174:3408-3415.
115. Sarraj B., Ye J., Akl A.I., Chen G., Wang J.J., Zhang Z., Abadja F., Abecassis M., Miller S.D., Kansas G.S., Ansari M.J. Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proc. Natl. Acad. Sci. USA 2014, 111:12145-12150.
116. Schenk A.D., Gorbacheva V., Rabant M., Fairchild R.L., Valujskikh A. Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am. J. Transplant. 2009, 9:64-73.
117. Schmidt E.M., Wang C.J., Ryan G.A., Clough L.E., Qureshi O.S., Goodall M., Abbas A.K., Sharpe A.H., Sansom D.M., Walker L.S. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J. Immunol. 2009, 182:274-282.
118. Setoguchi K., Schenk A.D., Ishii D., Hattori Y., Baldwin W.M., Tanabe K., Fairchild R.L. LFA-1 Antagonism Inhibits Early Infiltration of Endogenous Memory CD8 T Cells into Cardiac Allografts and Donor-Reactive T Cell Priming. Am J Transplant. 2011, 11:923-935.
119. Shin J.S., Kim J.M., Kim J.S., Min B.H., Kim Y.H., Kim H.J., Jang J.Y., Yoon I.H., Kang H.J., Kim J., et al. Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am. J. Transplant. 2015, 15:2837-2850.
120. Singh K., Kozyr N., Stempora L., Kirk A.D., Larsen C.P., Blazar B.R., Kean L.S. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am. J. Transplant. 2012, 12:1441-1457.
121. Suchard S.J., Davis P.M., Kansal S., Stetsko D.K., Brosius R., Tamura J., Schneeweis L., Bryson J., Salcedo T., Wang H., et al. A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J. Immunol. 2013, 191:4599-4610.
122. Sun J.C., Bevan M.J. Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J. Immunol. 2004, 172:3385-3389.
123. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
124. Tanaka K., Albin M.J., Yuan X., Yamaura K., Habicht A., Murayama T., Grimm M., Waaga A.M., Ueno T., Padera R.F., et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J. Immunol. 2007, 179:5204-5210.
125. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., Zheng X.X., Strom T.B., Bluestone J.A. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 2003, 171:3348-3352.
126. Thompson P., Cardona K., Russell M., Badell I.R., Shaffer V., Korbutt G., Rayat G.R., Cano J., Song M., Jiang W., et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am. J. Transplant. 2011, 11:947-957.
127. Thompson P., Badell I.R., Lowe M., Turner A., Cano J., Avila J., Azimzadeh A., Cheng X., Pierson R.N., Johnson B., et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am. J. Transplant. 2012, 12:1765-1775.
128. Thornley T.B., Fang Z., Balasubramanian S., Larocca R.A., Gong W., Gupta S., Csizmadia E., Degauque N., Kim B.S., Koulmanda M., et al. Fragile TIM-4-expressing tissue resident macrophages are migratory and immunoregulatory. J. Clin. Invest. 2014, 124:3443-3454.
129. Trambley J., Bingaman A.W., Lin A., Elwood E.T., Waitze S.Y., Ha J., Durham M.M., Corbascio M., Cowan S.R., Pearson T.C., Larsen C.P. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J. Clin. Invest. 1999, 104:1715-1722.
130. Turgeon N.A., Avila J.G., Cano J.A., Hutchinson J.J., Badell I.R., Page A.J., Adams A.B., Sears M.H., Bowen P.H., Kirk A.D., et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am. J. Transplant. 2010, 10:2082-2091.
131. Uchida Y., Ke B., Freitas M.C., Yagita H., Akiba H., Busuttil R.W., Najafian N., Kupiec-Weglinski J.W. T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology 2010, 139:2195-2206.
132. Ueno T., Habicht A., Clarkson M.R., Albin M.J., Yamaura K., Boenisch O., Popoola J., Wang Y., Yagita H., Akiba H., et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J. Clin. Invest. 2008, 118:742-751.
133. Vaidya S.V., Stepp S.E., McNerney M.E., Lee J.K., Bennett M., Lee K.M., Stewart C.L., Kumar V., Mathew P.A. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J. Immunol. 2005, 174:800-807.
134. Valujskikh A., Pantenburg B., Heeger P.S. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2002, 2:501-509.
135. van der Merwe P.A. A subtle role for CD2 in T cell antigen recognition. J. Exp. Med. 1999, 190:1371-1374.
136. Vanrenterghem Y., Bresnahan B., Campistol J., Durrbach A., Grinyó J., Neumayer H.H., Lang P., Larsen C.P., Mancilla-Urrea E., Pestana J.M., et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011, 91:976-983.
137. Venner J.M., Famulski K.S., Badr D., Hidalgo L.G., Chang J., Halloran P.F. Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am. J. Transplant. 2014, 14:2565-2576.
138. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., Lang P., Grinyo J., Halloran P.F., Solez K., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 2005, 353:770-781. Belatacept Study Group.
139. Vincenti F., Mendez R., Pescovitz M., Rajagopalan P.R., Wilkinson A.H., Butt K., Laskow D., Slakey D.P., Lorber M.I., Garg J.P., Garovoy M. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am. J. Transplant. 2007, 7:1770-1777.
140. Vincenti F., Charpentier B., Vanrenterghem Y., Rostaing L., Bresnahan B., Darji P., Massari P., Mondragon-Ramirez G.A., Agarwal M., Di Russo G., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 2010, 10:535-546.
141. Vincenti F., Rostaing L., Grinyo J., Rice K., Steinberg S., Gaite L., Moal M.C., Mondragon-Ramirez G.A., Kothari J., Polinsky M.S., et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N. Engl. J. Med. 2016, 374:333-343.
142. Vu M.D., Clarkson M.R., Yagita H., Turka L.A., Sayegh M.H., Li X.C. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J. Immunol. 2006, 176:1394-1401.
143. Vu M.D., Xiao X., Gao W., Degauque N., Chen M., Kroemer A., Killeen N., Ishii N., Li X.C. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007, 110:2501-2510.
144. Waggoner S.N., Taniguchi R.T., Mathew P.A., Kumar V., Welsh R.M. Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 2010, 120:1925-1938.
145. Wang L., Han R., Hancock W.W. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. Eur. J. Immunol. 2007, 37:2983-2990.
146. Wang N., Calpe S., Westcott J., Castro W., Ma C., Engel P., Schatzle J.D., Terhorst C. Cutting edge: The adapters EAT-2A and -2B are positive regulators of CD244- and CD84-dependent NK cell functions in the C57BL/6 mouse. J. Immunol. 2010, 185:5683-5687.
147. Wang L., Rubinstein R., Lines J.L., Wasiuk A., Ahonen C., Guo Y., Lu L.F., Gondek D., Wang Y., Fava R.A., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011, 208:577-592.
148. Wang C.J., Heuts F., Ovcinnikovs V., Wardzinski L., Bowers C., Schmidt E.M., Kogimtzis A., Kenefeck R., Sansom D.M., Walker L.S. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc. Natl. Acad. Sci. USA 2015, 112:524-529.
149. Weaver T.A., Charafeddine A.H., Agarwal A., Turner A.P., Russell M., Leopardi F.V., Kampen R.L., Stempora L., Song M., Larsen C.P., Kirk A.D. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat. Med. 2009, 15:746-749.
150. Weng N.P., Akbar A.N., Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol. 2009, 30:306-312.
151. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., Subramaniam S., Blattman J.N., Barber D.L., Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:CD8.
152. Willecke F., Tiwari S., Rupprecht B., Wolf D., Hergeth S., Hoppe N., Dufner B., Schulte L., Anto Michel N., Bukosza N., et al. Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb. Haemost. 2014, 112:379-389.
153. Wing J.B., Ise W., Kurosaki T., Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 2014, 41:1013-1025.
154. Wolf D., Hohmann J.D., Wiedemann A., Bledzka K., Blankenbach H., Marchini T., Gutte K., Zeschky K., Bassler N., Hoppe N., et al. Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. Circ. Res. 2011, 109:1269-1279.
155. Xu H., Li X., Liu D., Li J., Zhang X., Chen X., Hou S., Peng L., Xu C., Liu W., et al. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature 2013, 496:523-527.
156. Yamada A., Kishimoto K., Dong V.M., Sho M., Salama A.D., Anosova N.G., Benichou G., Mandelbrot D.A., Sharpe A.H., Turka L.A., et al. CD28-independent costimulation of T cells in alloimmune responses. J. Immunol. 2001, 167:140-146.
157. Yang J., Popoola J., Khandwala S., Vadivel N., Vanguri V., Yuan X., Dada S., Guleria I., Tian C., Ansari M.J., et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 2008, 117:660-669.
158. Yang J., Riella L.V., Chock S., Liu T., Zhao X., Yuan X., Paterson A.M., Watanabe T., Vanguri V., Yagita H., et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J. Immunol. 2011, 187:1113-1119.
159. Yao S., Zhu Y., Zhu G., Augustine M., Zheng L., Goode D.J., Broadwater M., Ruff W., Flies S., Xu H., et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011, 34:729-740.
160. Yeung M.Y., McGrath M., Najafian N. The emerging role of the TIM molecules in transplantation. Am. J. Transplant. 2011, 11:2012-2019.
161. Yeung M.Y., McGrath M.M., Nakayama M., Shimizu T., Boenisch O., Magee C.N., Abdoli R., Akiba H., Ueno T., Turka L.A., Najafian N. Interruption of dendritic cell-mediated TIM-4 signaling induces regulatory T cells and promotes skin allograft survival. J. Immunol. 2013, 191:4447-4455.
162. Yeung M.Y., Ding Q., Brooks C.R., Xiao S., Workman C.J., Vignali D.A., Ueno T., Padera R.F., Kuchroo V.K., Najafian N., Rothstein D.M. TIM-1 signaling is required for maintenance and induction of regulatory B cells. Am. J. Transplant. 2015, 15:942-953.
163. Yuan X., Ansari M.J., D'Addio F., Paez-Cortez J., Schmitt I., Donnarumma M., Boenisch O., Zhao X., Popoola J., Clarkson M.R., et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc. Natl. Acad. Sci. USA 2009, 106:10734-10739.
164. Zhang N., Schröppel B., Lal G., Jakubzick C., Mao X., Chen D., Yin N., Jessberger R., Ochando J.C., Ding Y., Bromberg J.S. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009, 30:458-469.
165. Zhang T., Fresnay S., Welty E., Sangrampurkar N., Rybak E., Zhou H., Cheng X.F., Feng Q., Avon C., Laaris A., et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am. J. Transplant. 2011, 11:1599-1609.
166. Zhang R., Huynh A., Whitcher G., Chang J., Maltzman J.S., Turka L.A. An obligate cell-intrinsic function for CD28 in Tregs. J. Clin. Invest. 2013, 123:580-593.
167. Zirlik A., Maier C., Gerdes N., MacFarlane L., Soosairajah J., Bavendiek U., Ahrens I., Ernst S., Bassler N., Missiou A., et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007, 115:1571-1580.